Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 187 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PARP Inhibitor Clear all

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: ART6043, Olaparib; Drug
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 4 more

Conditions: Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer
Interventions: CYH33; Drug
Lead sponsor: Haihe Biopharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: New Haven, Connecticut • Dallas, Texas • Houston, Texas

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Talazoparib; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 35
States / cities: Duarte, California • Irvine, California • La Jolla, California + 28 more

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Olaparib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pancreatic Acinar Cell Carcinoma
Interventions: Olaparib, ECG, CT CAP, Tumor Biopsy; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer Metastatic
Interventions: Telaglenastat, Talazoparib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumor
Interventions: Prexasertib, Olaparib; Drug
Lead sponsor: Geoffrey Shapiro, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer
Interventions: AZD2281, AZD5363, AZD1775, AZD6738; Drug
Lead sponsor: Joseph Paul Eder; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: New Haven, Connecticut • Boston, Massachusetts • Cleveland, Ohio + 1 more

Conditions: Prostate Cancer, Endometrial Cancer
Interventions: Rucaparib, Nivolumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Uterine Corpus Leiomyosarcoma
Interventions: Computed Tomography, Core Biopsy, Magnetic Resonance Imaging, Olaparib, Temozolomide; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 15
States / cities: Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 11 more

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rucaparib, Enzalutamide, Abiraterone; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia • Minneapolis, Minnesota • Nashville, Tennessee

Conditions: Ovarian Cancer
Interventions: olaparib, paclitaxel, carboplatin, Drug: carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 125 Years · Female only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 8
States / cities: Stanford, California • West Hollywood, California • Orlando, Florida + 4 more

Conditions: Advanced Solid Tumor, Non-small Cell Lung Cancers
Interventions: Adagrasib, Olaparib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Neoplasm
Interventions: KU-0059436 (AZD2281)(PARP inhibitor); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more

Conditions: Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions: CB-839, Talazoparib; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more

Conditions: Non-small Cell Lung Cancer Stage III
Interventions: Paclitaxel, Placebo for Veliparib, Carboplatin, Veliparib, Radiotherapy; Drug · Radiation
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 12
States / cities: La Jolla, California • Newark, Delaware • Chicago, Illinois + 8 more

Conditions: Ovarian Cancer
Interventions: Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 46
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 26 more

Conditions: Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Cediranib, Ceralasertib, Olaparib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Breast Carcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Triple-Negative Breast Carcinoma, Refractory Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Serous Adenocarcinoma, Refractory Primary Peritoneal Serous Adenocarcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable High Grade Fallopian Tube Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Primary Peritoneal Serous Adenocarcinoma
Interventions: Olaparib, Onalespib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 2 more

Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor, Hedgehog Inhibitor
Interventions: Vismodegib, Atezolizumab; Drug
Lead sponsor: Ronald Buckanovich; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ovarian Cancer
Interventions: Alpelisib, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 16
States / cities: Phoenix, Arizona • Fort Myers, Florida • West Palm Beach, Florida + 10 more

Conditions: Advanced Solid Tumor
Interventions: M9466, Tuvusertib, Abiraterone acetate, Prednisone/Prednisolone; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer
Interventions: Active comparator: Niraparib, placebo; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms
Interventions: Lu-177-DOTATATE, Olaparib, Ga dotatate scanning, FDG-PET scanning, Amino Acid infusion; Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Telaglenastat + Talazoparib In Prostate Cancer

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

OLAParib COmbinations

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)